Ocumetics Amends Terms of Brokered Financing to Raise Up to $2.9 Million

An announcement from Ocumetics Technology Corp ( (TSE:OTC) ) is now available.

Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement led by Centurion One Capital, now planning to issue up to 4,166,666 units at $0.60 per unit for gross proceeds of up to $2.5 million, with each unit comprising one common share and a three-year warrant exercisable at $0.75. The company has also granted the lead agent an option to sell an additional 625,000 units for up to $375,000, expects to close the financing around December 29, 2025 subject to regulatory approvals, and intends to use the proceeds primarily to fund first-in-human clinical trials, ongoing R&D and general corporate purposes, with potential insider participation under related-party transaction exemptions.

Spark’s Take on TSE:OTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Underperform.

Ocumetics Technology Corp is facing significant financial challenges, marked by a lack of revenue generation, negative profitability, and a strained balance sheet with high liabilities. Technical analysis indicates a neutral trend with potential for slight upward movement, but valuation metrics remain unattractive. Recent corporate events show positive strategic developments, but they are not sufficient to outweigh the overall financial instability.

To see Spark’s full report on TSE:OTC stock, click here.

More about Ocumetics Technology Corp

Ocumetics Technology Corp. is a Calgary-based medical technology company focused on advanced ophthalmic solutions, including innovative intraocular lens technologies, with its current efforts centered on progressing products into human clinical trials.

Average Trading Volume: 42,831

Technical Sentiment Signal: Buy

Current Market Cap: C$31.44M

For detailed information about OTC stock, go to TipRanks’ Stock Analysis page.